Home > Insider Trading > Filing (0001144204-10-008526)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1114220	Keryx Biopharmaceuticals Inc	KERX	Pharmaceutical Preparations (2834)	134087132

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1038977	S Michael Weiss	787 Seventh Avenue New York NY 10019		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2009-01-28	51,300	$3.06	1,913,700	No	5	S	Direct
Common Stock	Disposition	2009-02-03	25,714	$2.70	1,887,986	No	5	S	Direct
Common Stock	Disposition	2009-12-07	165,000	$3.30	1,722,986	No	5	S	Direct
Common Stock	Acquisiton	2009-12-16	335,281	$0.00	2,058,267	No	5	J	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	5	S	Direct
No	5	S	Direct
No	5	S	Direct
No	5	J	Direct

Footnotes

The shares were received pursuant to that certain merger agreement (the "Agreement") between Keryx Biopharmaceuticals Inc. ("Keryx") and ACCESS Oncology, Inc. ("ACCESS") dated January 7, 2004, as amended. Under the terms of the Agreement, the common stockholders of ACCESS did not receive any compensation at the time the merger closed, but are due to receive common stock in Keryx upon the achievement of certain milestones. This issuance of Keryx common stock to Mr. Weiss represents the first milestone payment under the Agreement, and was triggered by the initiation of a Phase 3 registration trial of KRX-0401 (perifosine).
Based on a closing price of $2.73 per share on December 16, 2009, the 335,281 shares issued to Mr. Weiss were valued at $915,317.13.